Phathom Pharmaceuticals (PHAT) Projected to Release Earnings on Thursday

Phathom Pharmaceuticals (NASDAQ:PHAT) is anticipated to post its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to post earnings of $0.07 per share and revenue of $84.82 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:00 AM ET.

Phathom Pharmaceuticals Price Performance

PHAT opened at $5.94 on Tuesday. Phathom Pharmaceuticals has a fifty-two week low of $5.01 and a fifty-two week high of $18.31. The company’s 50-day moving average is $7.96 and its 200 day moving average is $10.72.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a research report on Thursday, October 15th. Leerink Partners initiated coverage on shares of Phathom Pharmaceuticals in a research note on Wednesday, September 9th. They issued a “market perform” rating and a $10.00 target price on the stock. Needham & Company LLC cut their price target on shares of Phathom Pharmaceuticals from $28.00 to $22.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Barclays cut their price target on shares of Phathom Pharmaceuticals from $18.00 to $14.00 and set an “overweight” rating for the company in a research note on Friday, August 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $26.00 price target on shares of Phathom Pharmaceuticals in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Phathom Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $20.11.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc (NASDAQ: PHAT) is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. The company’s principal product is Voquezna (vonoprazan), a potassium-competitive acid blocker designed to suppress stomach acid through a mechanism distinct from traditional proton pump inhibitors.

In the United States, Voquezna is approved for the treatment of Helicobacter pylori infection in combination with antibiotics and for certain forms of gastroesophageal reflux disease (GERD), including erosive esophagitis and heartburn associated with non-erosive GERD.